Core Insights - Onconetix, Inc. announced the acceptance of an abstract for presentation at the 2025 European Association of Urology (EAU) congress, focusing on the clinical performance of Proclarix in ruling out clinically insignificant or no prostate cancer [1][2] Company Overview - Onconetix, formerly known as Blue Water Biotech, is a cancer diagnostics company dedicated to the research, development, and commercialization of innovative oncology solutions [1][5] - The company has recently acquired Proteomedix, which developed Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the EU under the In Vitro Diagnostic Regulation (IVDR) [5] Product Details - Proclarix is a CE-certified blood test indicated for prostate cancer diagnosis in patients with normal digital rectal exams, enlarged prostate volume, and elevated PSA levels between 2-10 ng/ml [4] - The test combines in-vitro assays for quantitative detection of biomarkers with a proprietary algorithm to assess the risk of clinically significant prostate cancer [4] - Proclarix has shown reliability in multiple clinical studies as an indicator of clinically significant prostate cancer and is included in both European and American guidelines [4] Presentation Information - The presentation titled "Clinical Performance of Proclarix in Ruling Out Clinically Insignificant or No Prostate Cancer: Evaluation in a Danish Cohort" will take place on March 23, 2025, at the EAU congress [2][3] - The study involved over 800 patients from Lillebaelt Hospital - University Hospital of Southern Denmark [2]
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress